Pfizer Inc is in discussions with 90 nations over provide contracts for its experimental COVID-19 tablet, which was proven to cut back by 89% the chance of hospitalization or dying in sufferers at excessive threat of extreme sickness, Chief Govt Officer Albert Bourla mentioned in an interview on Friday.
He mentioned Pfizer expects to cost its therapy, known as Paxlovid, near the place rival Merck & Co Inc has priced its oral antiviral drug candidate.
Merck’s U.S. contract worth for its tablet molnupiriavr is round $700 for a five-day course of remedy.